Royce & Associates LP Purchases 1,000 Shares of CareDx, Inc (NASDAQ:CDNA)

Royce & Associates LP raised its position in shares of CareDx, Inc (NASDAQ:CDNA) by 0.3% during the third quarter, HoldingsChannel.com reports. The fund owned 393,286 shares of the company’s stock after buying an additional 1,000 shares during the quarter. Royce & Associates LP’s holdings in CareDx were worth $12,280,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. ClariVest Asset Management LLC boosted its position in CareDx by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 64,027 shares of the company’s stock valued at $994,000 after acquiring an additional 1,810 shares during the last quarter. GAMMA Investing LLC boosted its position in CareDx by 1,021.8% during the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after acquiring an additional 2,013 shares during the last quarter. nVerses Capital LLC boosted its position in CareDx by 175.0% during the third quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock valued at $103,000 after acquiring an additional 2,100 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in CareDx by 8.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,396 shares of the company’s stock valued at $312,000 after acquiring an additional 2,344 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in CareDx by 13.4% during the second quarter. Allspring Global Investments Holdings LLC now owns 21,164 shares of the company’s stock valued at $329,000 after acquiring an additional 2,503 shares during the last quarter.

CareDx Price Performance

CDNA opened at $21.17 on Friday. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The firm has a market capitalization of $1.14 billion, a PE ratio of -7.84 and a beta of 1.80. The company’s 50-day moving average is $26.68 and its 200 day moving average is $21.70.

CareDx (NASDAQ:CDNA) last posted its earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $82.88 million for the quarter, compared to analyst estimates of $80.04 million. During the same quarter in the prior year, the business posted ($0.43) EPS. The firm’s revenue was up 23.4% compared to the same quarter last year. As a group, analysts expect that CareDx, Inc will post -0.7 EPS for the current year.

Analysts Set New Price Targets

CDNA has been the topic of a number of research analyst reports. Craig Hallum upped their price target on shares of CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. The Goldman Sachs Group increased their price objective on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. HC Wainwright reissued a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. Wells Fargo & Company assumed coverage on shares of CareDx in a research report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price objective on the stock. Finally, BTIG Research cut their price objective on shares of CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.60.

Insider Buying and Selling

In other CareDx news, Director Peter Maag sold 35,552 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total value of $1,174,638.08. Following the completion of the sale, the director now owns 330,024 shares in the company, valued at approximately $10,903,992.96. This trade represents a 9.72 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alexander L. Johnson sold 34,231 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $33.55, for a total transaction of $1,148,450.05. Following the completion of the sale, the insider now owns 284,983 shares of the company’s stock, valued at approximately $9,561,179.65. This trade represents a 10.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 91,340 shares of company stock worth $3,025,415 in the last quarter. Insiders own 4.90% of the company’s stock.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.